Literature DB >> 7925820

Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.

U Muthane1, K A Ramsay, H Jiang, V Jackson-Lewis, D Donaldson, S Fernando, M Ferreira, S Przedborski.   

Abstract

The present study demonstrates that the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes significantly greater reductions in striatal dopamine levels in C57/bl mice than in CD-1 mice, thus confirming a greater sensitivity of the C57/bl mice to MPTP. To determine the possible reasons for this difference in MPTP sensitivity between these two mouse strains, we have compared both the organization and the number of substantia nigra (SN) neurons, the primary target of MPTP, in C57/bl and in CD-1 mice using immunostaining for tyrosine hydroxylase (TH) and calbindin-D28k (calbindin). In saline-injected animals, there is a significantly lower number of SN TH-positive and calbindin-positive neurons in C57/bl than CD-1 mice; no significant differences in the numbers of these neurons are found in the ventral tegmental area between the two strains. In MPTP-injected animals, the reductions in SN TH-positive neurons are significantly greater in C57/bl than in CD-1 mice. In contrast, MPTP does not cause any significant changes in the numbers of SN calbindin-positive neurons in either strain. The present study shows that C57/bl mice which have fewer SN TH-positive neurons are more sensitive to MPTP-induced toxicity than CD-1 mice. This observation suggests a possible inverse relationship between SN TH-positive neuron number and MPTP sensitivity. If correct, this hypothesis may be of major importance for Parkinson's disease since it is suggested that individuals at risk of developing this neurodegenerative disorder may have lower numbers of SN TH-positive neurons to start with. The present study also shows that SN calbindin-positive neurons are spared following MPTP administration. However, the observed difference in SN calbindin-positive neuron numbers does not account for the differential sensitivity to MPTP between these two mouse strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925820     DOI: 10.1006/exnr.1994.1058

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  30 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Exercise protects against MPTP-induced neurotoxicity in mice.

Authors:  Kimberly M Gerecke; Yun Jiao; Amar Pani; Vishwajeeth Pagala; Richard J Smeyne
Journal:  Brain Res       Date:  2010-01-29       Impact factor: 3.252

3.  Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

Authors:  Maryna Baydyuk; Madeline T Nguyen; Baoji Xu
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

4.  Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.

Authors:  Justin D Boyd; Haeman Jang; Kennie R Shepherd; Ciaran Faherty; Sally Slack; Yun Jiao; Richard J Smeyne
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

5.  A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse.

Authors:  Z C Baquet; D Williams; J Brody; R J Smeyne
Journal:  Neuroscience       Date:  2009-04-17       Impact factor: 3.590

Review 6.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

7.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

8.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

9.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Eric J Benner; R Lee Mosley; Chris J Destache; Travis B Lewis; Vernice Jackson-Lewis; Santhi Gorantla; Craig Nemachek; Steven R Green; Serge Przedborski; Howard E Gendelman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.